Sanyou Bio and BioGeometry Team Up to Develop Innovative Antibody Drug Discovery Platform Driven by AIGC
Overview
BioGeometry and Sanyou Bio recently announced a strategic partnership agreement, signifying a significant collaboration in biotechnology.
BioGeometry
- BioGeometry, a digital biology pioneer, specializes in AI-driven protein design and research and development platforms.
- Sanyou Bio, on the other hand, is a prominent biotechnology enterprise focusing on innovative biologic drug research and services.
Aim for Partnership
- The partnership aims to leverage both companies' expertise in generative AI technology and practical drug development experience to create a next-generation antibody drug discovery platform driven by AI.
- They intend to collaborate with leading pharmaceutical companies to enhance the efficiency of new drug research and development.
Both Parties Post Agreement
- Sanyou Bio will integrate BioGeometry's proprietary generative AI antibody design platform, GeoBiologics, into its operations.
- Both parties will invest to create an advanced Dry-Wet antibody R&D platform by merging BioGeometry's AI algorithm dry lab platform with Sanyou Bio's wet lab capabilities.
- This platform will facilitate the development of more large molecule drug pipelines and nurture innovative projects.
Sanyou Bio has established a high-throughput R&D platform for innovative antibody drugs, boasting the world's largest antibody library and cutting-edge technical resources. Their platform integrates various molecule generation technologies and automated screening processes, focusing on generating molecules with superior characteristics.
Deep Learning Models by Biogeometry
- BioGeometry has developed geometric deep learning models that significantly reduce time and costs in antibody design.
- Their GeoBiologics platform facilitates a closed-loop between dry and wet lab experiments, enhancing efficiency in discovering functional molecules.
Dr. Guojun Lang, CEO of Sanyou Bio, expressed confidence in BioGeometry's AI technology to transform their R&D platform, enhancing their competitiveness in new drug discovery.
CEO of Biogeometry on New Drug R&d
Dr. Jian Tang, CEO of BioGeometry, emphasized the joint creation of a cutting-edge AI-enabled antibody discovery platform with Sanyou Bio, aiming to revolutionize new drug R&D and accelerate advancements in antibody drug research.
Conclusion
In summary, the strategic partnership between BioGeometry and Sanyou Bio marks a new era of collaboration in biotechnology, with a focus on innovation and efficiency in drug discovery and development.
